Updates in Locally Advanced Pancreatic Cancer
Pancreatic cancer is the 4th leading cancer cause mortality in both men and women. Pancreatic cancer is usually diagnosed in the advanced setting, and only 10-15% of patients present with operable disease. About 25% are locally advanced and unresectable and the rest are metastatic. Studies presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting highlighted both current treatment options and promising novel therapeutic agents and approaches.
Image: Design of the ongoing UK SCALOP phase II study.
Heinemann V, Ebert MP, Pinter T, Bevan P, Neville NG, Mala C. Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):4060.
Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 2006; 4:159-67. [PMID 16547153]
Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer 2004; 110:815-24. [PMID 15170662]
Setyono-Han B, Sturzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005; 93:779-86. [PMID 15841327]
Jiang Y, Kimchi E, Gusani NJ, Mackley HB, Staveley-O'Carroll K. Phase I study of capecitabine and erlotinib with radiotherapy in locally advanced nonoperable pancreatic cancer. J Clin Oncol 2010; 28(Suppl):e14680.
Loehrer PJ Sr, Powell ME, Cardenes HR, Wagner L, Brell LJM, Ramanathan RK, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; 26(15 Suppl):4506.
Ioka T, Ikeda M, Ito Y, Yonemoto N, Nagase M, Yamao K, et al. A multicenter phase II trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):4058.
Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-57. [PMID 8862723]
Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 2010; 40:567-72. [PMID 20189975]
Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23:6957-65. [PMID 16145066]
Mukherjee S, Hurt C, Griffiths G, Crosby T, Staffurth J, Bridges S, et al. A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):TPS222.
Desai S, Ben-Josef E, Griffith KA, Simeone D, Greenson JK, Francis IR, et al. Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys 2009; 75:1450-5. [PMID 19409732]
Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005; 23:8679-87. [PMID 16314628]
Moureau-Zabotto L, Phélip J, Afchain P, Mineur L, André T, Vendrely V, et al. Concomitant administration of weekly oxaliplatin, 5FU continuous infusion and radiotherapy in locally advanced pancreatic cancer (LAPC): A GERCOR phase II study. J Clin Oncol 2006; 24(18 Suppl):4039.
Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110:47-55. [PMID 17538975]
Anderson S, Cardenes HR, Akisik F, Johnston EL, Clark R, Perkins SM, et al. Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC). J Clin Oncol 2010; 28(15 Suppl):4139.
Wallace JA, Locker G, Nattam S, Kasza K, Wade-Oliver K, Stadler WM, et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 2007; 25(18 Suppl):4608.
Lund EL, Høg A, Olsen MW, Hansen LT, Engelholm SA, Kristjansen PE. Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer 2004; 108:833-8. [PMID 14712484]
Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW. Activation of Raf by ionizing radiation. Nature 1966; 382:813-6. [PMID 8752275]
Nio K, Ueno H, Okusaka T, Morizane C, Hagihara A, Kondo S, et al. Chemoradiotherapy versus gemcitabine-based chemotherapy in patients with unresectable, locally advanced pancreatic cancer. J Clin Oncol 2010; 28(Suppl):e14504.
Chang BW, Saif MW. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap? JOP. J Pancreas (Online) 2009; 10:231-6. [PMID 19454812]
Copyright (c) 2010 Bryan W Chang, Eduardo Siccion, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.